CD8A and neoplasm: When we did not inject mice with PBMC and CD8+ T cell administration, no significant difference in PC3 tumor growth was observed between animals treated with anti-Siglec-7 and -9 mAb and IgG1 isotype treated controls (Figure 5, H–L), demonstrating that growth suppression was dependent on activity of the human immune cells.